Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Return on Equity (2016 - 2025)

Historic Return on Equity for Harvard Bioscience (HBIO) over the last 15 years, with Q3 2025 value amounting to 3.61%.

  • Harvard Bioscience's Return on Equity fell 33900.0% to 3.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.61%, marking a year-over-year decrease of 33900.0%. This contributed to the annual value of 0.18% for FY2024, which is 1300.0% down from last year.
  • Per Harvard Bioscience's latest filing, its Return on Equity stood at 3.61% for Q3 2025, which was down 33900.0% from 3.75% recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Return on Equity registered a high of 0.01% during Q4 2021, and its lowest value of 3.75% during Q2 2025.
  • Over the past 5 years, Harvard Bioscience's median Return on Equity value was 0.09% (recorded in 2022), while the average stood at 0.54%.
  • As far as peak fluctuations go, Harvard Bioscience's Return on Equity surged by 900bps in 2021, and later crashed by -35900bps in 2025.
  • Over the past 5 years, Harvard Bioscience's Return on Equity (Quarter) stood at 0.01% in 2021, then crashed by -1589bps to 0.14% in 2022, then skyrocketed by 66bps to 0.05% in 2023, then plummeted by -309bps to 0.19% in 2024, then plummeted by -1783bps to 3.61% in 2025.
  • Its last three reported values are 3.61% in Q3 2025, 3.75% for Q2 2025, and 1.48% during Q1 2025.